Pharmaron Beijing Co Ltd (300759) - Total Assets
Based on the latest financial reports, Pharmaron Beijing Co Ltd (300759) holds total assets worth CN¥25.80 Billion CNY (≈ $3.78 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharmaron Beijing Co Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Pharmaron Beijing Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Pharmaron Beijing Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Pharmaron Beijing Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Pharmaron Beijing Co Ltd's total assets of CN¥25.80 Billion consist of 31.8% current assets and 68.2% non-current assets. Review 300759 liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.1% |
| Accounts Receivable | CN¥3.03 Billion | 12.7% |
| Inventory | CN¥1.12 Billion | 4.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥791.00 Million | 3.3% |
| Goodwill | CN¥2.76 Billion | 11.5% |
Asset Composition Trend (2014–2024)
This chart illustrates how Pharmaron Beijing Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Pharmaron Beijing Co Ltd stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharmaron Beijing Co Ltd's current assets represent 31.8% of total assets in 2024, a decrease from 36.6% in 2014.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2024, up from 4.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 2.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 12.7% of total assets.
Pharmaron Beijing Co Ltd Competitors by Total Assets
Key competitors of Pharmaron Beijing Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $4.32 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Pharmaron Beijing Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.50 | 1.71 | 2.80 |
| Quick Ratio | 1.24 | 1.42 | 2.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.62 Billion | CN¥2.94 Billion | CN¥3.56 Billion |
Pharmaron Beijing Co Ltd - Advanced Valuation Insights
This section examines the relationship between Pharmaron Beijing Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.84 |
| Latest Market Cap to Assets Ratio | 0.37 |
| Asset Growth Rate (YoY) | -9.6% |
| Total Assets | CN¥23.93 Billion |
| Market Capitalization | $8.92 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Pharmaron Beijing Co Ltd's assets below their book value (0.37x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pharmaron Beijing Co Ltd's assets decreased by 9.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pharmaron Beijing Co Ltd (2014–2024)
The table below shows the annual total assets of Pharmaron Beijing Co Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥23.93 Billion ≈ $3.50 Billion |
-9.63% |
| 2023-12-31 | CN¥26.48 Billion ≈ $3.87 Billion |
+29.20% |
| 2022-12-31 | CN¥20.49 Billion ≈ $3.00 Billion |
+11.44% |
| 2021-12-31 | CN¥18.39 Billion ≈ $2.69 Billion |
+54.42% |
| 2020-12-31 | CN¥11.91 Billion ≈ $1.74 Billion |
+19.87% |
| 2019-12-31 | CN¥9.94 Billion ≈ $1.45 Billion |
+114.79% |
| 2018-12-31 | CN¥4.63 Billion ≈ $676.85 Million |
+18.02% |
| 2017-12-31 | CN¥3.92 Billion ≈ $573.50 Million |
+39.74% |
| 2016-12-31 | CN¥2.80 Billion ≈ $410.40 Million |
+138.78% |
| 2015-12-31 | CN¥1.17 Billion ≈ $171.87 Million |
+26.10% |
| 2014-12-31 | CN¥931.46 Million ≈ $136.30 Million |
-- |
About Pharmaron Beijing Co Ltd
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more